Last update
5/1/2026
Reviewed By
Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 33 Researches
7.4
USERS' SCORE
Moderately Good
Based on 10 Reviews
7.9
Supplement Facts
Serving Size: 2 Softgels
Serving Per Container: 120
Amount Per Serving
%DV
Calories
20
Total Fat
2 g
3%‡
Cholesterol
11 mg
4%‡
Protein
<1 g
Fish Oil Concentrate^
2,000 mg
†
Omega-3 Fatty Acids^
1,200 mg
†
EPA (Eicosapentaenoic Acid)^
800 mg
†
DHA (Docosahexaenoic Acid)^
400 mg
†
Top Medical Research Studies
9
We investigated the link between plasma omega-3 levels and the risk of heart failure (HF) in a large UK cohort study. Our analysis revealed that higher omega-3 levels were associated with a 21% lower chance of developing HF over nearly 14 years.
For individuals already diagnosed with HF, elevated omega-3 levels corresponded to about a 50% reduction in the risk of overall and cardiovascular mortality. These results suggest that boosting omega-3 intake through diet or supplements may help prevent HF and increase longevity for those already facing heart challenges.
For individuals already diagnosed with HF, elevated omega-3 levels corresponded to about a 50% reduction in the risk of overall and cardiovascular mortality. These results suggest that boosting omega-3 intake through diet or supplements may help prevent HF and increase longevity for those already facing heart challenges.
Read More
9
Omega-3 reduces cardiovascular risk
We observed the effects of icosapent ethyl on heart health in a significant clinical trial involving statin-treated patients at high risk for cardiovascular events. This post hoc analysis revealed that icosapent ethyl reduced major cardiovascular issues, regardless of whether patients had low-density lipoprotein cholesterol (LDL-C) levels below or above 55 mg/dL.
Notably, those with optimal LDL-C control still benefited from the treatment, showing that this fish oil derivative can be effective in managing heart risks for many patients.
Notably, those with optimal LDL-C control still benefited from the treatment, showing that this fish oil derivative can be effective in managing heart risks for many patients.
Read More
8
We explored the impact of eicosapentaenoic acid (EPA) on heart health by studying mice on a high-fat diet. Those supplemented with EPA showed a significant reduction in atrial fibrillation compared to those without. While 100% of the high-fat diet mice developed atrial fibrillation, only 50% of those receiving EPA did, and their episodes were shorter.
Our findings suggest that including EPA in the diet can help improve heart function and reduce irregular heart rhythms linked to high-fat diets.
Our findings suggest that including EPA in the diet can help improve heart function and reduce irregular heart rhythms linked to high-fat diets.
Read More
Most Useful Reviews
7.5
Optimised ratio
3 people found this helpful
I selected EPA-DHA Balance by Jarrow Formulas for its ideal EPA and DHA content, which promotes brain function, joint mobility, and mood enhancement. Each capsule comprises 400 mg of EPA and 200 mg of DHA. If allergic to fish, opt for a different omega source. I find it highly effective and recommend it.
Read More
9
Promotes heart health
1 people found this helpful
EPA-DHA Balance provides an excellent ratio of omega-3 fatty acids sourced from fish. It’s molecularly distilled to eliminate mercury, ensuring safety. I recommend these softgels for cardiovascular, joint, and skin health support.
Read More
7.5
Supports heart health
1 people found this helpful
EPA and DHA support cardiovascular health, brain function, and joint health, potentially improving mood.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 33 Researches
7.4
- All Researches
9
Omega-3 reduces cardiovascular risk
We observed the effects of icosapent ethyl on heart health in a significant clinical trial involving statin-treated patients at high risk for cardiovascular events. This post hoc analysis revealed that icosapent ethyl reduced major cardiovascular issues, regardless of whether patients had low-density lipoprotein cholesterol (LDL-C) levels below or above 55 mg/dL.
Notably, those with optimal LDL-C control still benefited from the treatment, showing that this fish oil derivative can be effective in managing heart risks for many patients.
Notably, those with optimal LDL-C control still benefited from the treatment, showing that this fish oil derivative can be effective in managing heart risks for many patients.
Read More
9
We assessed how omega-3 fatty acids (PUFAs) can support heart failure management through a thorough network meta-analysis of 14 studies with nearly 9,100 participants.
Our findings revealed that high doses (2,000-4,000 mg/day) taken for at least one year significantly improved heart function, particularly the left ventricular ejection fraction and peak oxygen consumption.
However, lower doses and shorter durations were not effective, and we found no major differences in safety measures like dropout rates or overall mortality between those taking omega-3 and those who were not.
Our findings revealed that high doses (2,000-4,000 mg/day) taken for at least one year significantly improved heart function, particularly the left ventricular ejection fraction and peak oxygen consumption.
However, lower doses and shorter durations were not effective, and we found no major differences in safety measures like dropout rates or overall mortality between those taking omega-3 and those who were not.
Read More
9
We investigated the link between plasma omega-3 levels and the risk of heart failure (HF) in a large UK cohort study. Our analysis revealed that higher omega-3 levels were associated with a 21% lower chance of developing HF over nearly 14 years.
For individuals already diagnosed with HF, elevated omega-3 levels corresponded to about a 50% reduction in the risk of overall and cardiovascular mortality. These results suggest that boosting omega-3 intake through diet or supplements may help prevent HF and increase longevity for those already facing heart challenges.
For individuals already diagnosed with HF, elevated omega-3 levels corresponded to about a 50% reduction in the risk of overall and cardiovascular mortality. These results suggest that boosting omega-3 intake through diet or supplements may help prevent HF and increase longevity for those already facing heart challenges.
Read More
9
We delved into how Antarctic krill oil, rich in eicosapentaenoic acid (EPA), can influence cardiovascular health, specifically in the context of obesity. Our focus centered on its effects in mice fed a high-fat diet, which typically leads to increased cholesterol levels and oxidative stress—conditions that can heighten cardiovascular disease risk.
Through our research methods, including molecular docking and analysis of liver histology, we discovered that Antarctic krill oil appears to play a beneficial role in combating these adverse effects. We observed that the oil reduced oxidative stress and fat accumulation in these obese mice. This was associated with improved metabolic parameters that contribute to heart health, primarily through its action on molecules involved in cholesterol metabolism.
Notably, we found that krill oil helped lower the levels of harmful low-density lipoprotein cholesterol and activated pathways that support good cholesterol management in the body. These findings suggest that incorporating Antarctic krill oil, with its high EPA content, might be a promising strategy for addressing obesity-related cardiovascular issues.
Overall, our study points to the potential of eicosapentaenoic acid from krill oil as a natural approach to improving heart health, particularly for those struggling with obesity and its challenges.
Through our research methods, including molecular docking and analysis of liver histology, we discovered that Antarctic krill oil appears to play a beneficial role in combating these adverse effects. We observed that the oil reduced oxidative stress and fat accumulation in these obese mice. This was associated with improved metabolic parameters that contribute to heart health, primarily through its action on molecules involved in cholesterol metabolism.
Notably, we found that krill oil helped lower the levels of harmful low-density lipoprotein cholesterol and activated pathways that support good cholesterol management in the body. These findings suggest that incorporating Antarctic krill oil, with its high EPA content, might be a promising strategy for addressing obesity-related cardiovascular issues.
Overall, our study points to the potential of eicosapentaenoic acid from krill oil as a natural approach to improving heart health, particularly for those struggling with obesity and its challenges.
Read More
8
This study examined how different fatty acids affect heart health, particularly focusing on long-chain acylcarnitines. We found that saturated and monounsaturated acylcarnitines, especially one type called trans-elaidoylcarnitine, can significantly harm heart function and cell viability.
On the other hand, omega-3 derived acylcarnitines like eicosapentaenoylcarnitine and docosahexaenoylcarnitine showed minimal negative effects. In fact, they did not impair heart function or cell viability, suggesting that omega-3 fish oil might be a safer option for people with heart issues compared to other fatty acid sources.
On the other hand, omega-3 derived acylcarnitines like eicosapentaenoylcarnitine and docosahexaenoylcarnitine showed minimal negative effects. In fact, they did not impair heart function or cell viability, suggesting that omega-3 fish oil might be a safer option for people with heart issues compared to other fatty acid sources.
Read More
User Reviews
USERS' SCORE
Moderately Good
Based on 10 Reviews
7.9
- All Reviews
- Positive Reviews
- Negative Reviews
7.5
Optimised ratio
3 people found this helpful
I selected EPA-DHA Balance by Jarrow Formulas for its ideal EPA and DHA content, which promotes brain function, joint mobility, and mood enhancement. Each capsule comprises 400 mg of EPA and 200 mg of DHA. If allergic to fish, opt for a different omega source. I find it highly effective and recommend it.
Read More
9
Promotes heart health
1 people found this helpful
EPA-DHA Balance provides an excellent ratio of omega-3 fatty acids sourced from fish. It’s molecularly distilled to eliminate mercury, ensuring safety. I recommend these softgels for cardiovascular, joint, and skin health support.
Read More
7.5
Supports heart health
1 people found this helpful
EPA and DHA support cardiovascular health, brain function, and joint health, potentially improving mood.
Read More
9
Highly potent omega-3s
I chose Jarrow Formulas EPA-DHA Balance due to its high potency of omega-3s, essential for cardiovascular disease and overall health. The 240 softgels provide an ample supply, and there's no fishy aftertaste, making it easy to take daily. They adhere to third-party testing for quality assurance. While the size may challenge some, I see this as a reliable omega-3 supplement for my needs.
Read More
9
Supports cardiovascular health
EPA-DHA Balance® comprises highly purified, concentrated omega-3 fatty acids from fish oil in a 2:1 ratio. It conforms to strict standards and is manufactured under Good Manufacturing Practices (GMP). The EPA and DHA support cardiovascular disease, brain function, and joint health, while potentially enhancing mood. I appreciate its quality, composition, and the lack of odour.
Read More
Frequently Asked Questions
9
Omega-3 reduces cardiovascular risk
We observed the effects of icosapent ethyl on heart health in a significant clinical trial involving statin-treated patients at high risk for cardiovascular events. This post hoc analysis revealed that icosapent ethyl reduced major cardiovascular issues, regardless of whether patients had low-density lipoprotein cholesterol (LDL-C) levels below or above 55 mg/dL.
Notably, those with optimal LDL-C control still benefited from the treatment, showing that this fish oil derivative can be effective in managing heart risks for many patients.
Notably, those with optimal LDL-C control still benefited from the treatment, showing that this fish oil derivative can be effective in managing heart risks for many patients.
8
We assessed the relationship between various serum metabolites and the occurrence of major adverse cardiovascular events (MACE) in middle-aged and elderly adults. One of the key metabolites we looked at was docosahexaenoic acid (DHA), which has been noted for its potential cardiovascular benefits.
Throughout our study involving over 54,000 UK Biobank participants, we found that DHA and some other metabolic markers were linked to MACE risk, particularly among middle-aged individuals. Interestingly, in the elderly, DHA showcased a protective role, revealing how certain metabolic factors may play a different part in heart health as we age.
Our research highlighted that while middle-aged adults exhibited various metabolic indicators associated with increased risk of cardiovascular issues, the elderly had fewer markers that correlated with heightened risk. DHA, in particular, seemed to stand out among the compounds that may help protect against MACE in older adults, as indicated by our findings.
Overall, this research sheds light on the complexity of how dietary components like DHA interact with age-related cardiovascular risks, suggesting a need for further studies into personalized approaches for preventing cardiovascular events tailored to different age groups.
Throughout our study involving over 54,000 UK Biobank participants, we found that DHA and some other metabolic markers were linked to MACE risk, particularly among middle-aged individuals. Interestingly, in the elderly, DHA showcased a protective role, revealing how certain metabolic factors may play a different part in heart health as we age.
Our research highlighted that while middle-aged adults exhibited various metabolic indicators associated with increased risk of cardiovascular issues, the elderly had fewer markers that correlated with heightened risk. DHA, in particular, seemed to stand out among the compounds that may help protect against MACE in older adults, as indicated by our findings.
Overall, this research sheds light on the complexity of how dietary components like DHA interact with age-related cardiovascular risks, suggesting a need for further studies into personalized approaches for preventing cardiovascular events tailored to different age groups.
4
Genetics influence omega-3 effectiveness
We aimed to evaluate how genetic factors influence the effectiveness of fish oil supplementation on fatty acid profiles in healthy individuals.
In this study, 86 adults participated in a 4-week fish oil program, and their lipid profiles were assessed before and after the supplementation.
We found that genetic variations, specifically in the FADS1 and ELOVL2 genes, might affect how well the body utilizes omega-3 fatty acids.
This highlights the potential for personalized nutrition to enhance cardiovascular health.
In this study, 86 adults participated in a 4-week fish oil program, and their lipid profiles were assessed before and after the supplementation.
We found that genetic variations, specifically in the FADS1 and ELOVL2 genes, might affect how well the body utilizes omega-3 fatty acids.
This highlights the potential for personalized nutrition to enhance cardiovascular health.
8
We explored the potential connection between eicosapentaenoic acid (EPA), which is an omega-3 fatty acid, and its role in reducing inflammation related to cardiovascular disease (CVD) in older adults. In our study, we measured the plasma levels of various omega-3 fatty acids and their specialized pro-resolving lipid mediators (SPMs) in a group of 21 older participants who exhibited low-grade chronic inflammation.
The findings were intriguing. We observed that higher levels of docosahexaenoic acid (DHA) were linked to lower concentrations of several inflammatory markers, including interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). Additionally, certain SPMs derived from EPA and DHA were also associated with reductions in inflammation levels, suggesting that these omega-3-derived substances might support the body's natural ability to resolve inflammation.
However, while the association between omega-3 fatty acids and inflammation was apparent, our study did not isolate the effects of EPA alone. This means we cannot definitively conclude the unique impact of eicosapentaenoic acid on cardiovascular health.
Overall, this research sheds light on how dietary intake of omega-3 fatty acids, particularly from sources rich in DHA and EPA, may benefit inflammation regulation—an important aspect of cardiovascular well-being.
The findings were intriguing. We observed that higher levels of docosahexaenoic acid (DHA) were linked to lower concentrations of several inflammatory markers, including interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). Additionally, certain SPMs derived from EPA and DHA were also associated with reductions in inflammation levels, suggesting that these omega-3-derived substances might support the body's natural ability to resolve inflammation.
However, while the association between omega-3 fatty acids and inflammation was apparent, our study did not isolate the effects of EPA alone. This means we cannot definitively conclude the unique impact of eicosapentaenoic acid on cardiovascular health.
Overall, this research sheds light on how dietary intake of omega-3 fatty acids, particularly from sources rich in DHA and EPA, may benefit inflammation regulation—an important aspect of cardiovascular well-being.
9
We assessed how omega-3 fatty acids (PUFAs) can support heart failure management through a thorough network meta-analysis of 14 studies with nearly 9,100 participants.
Our findings revealed that high doses (2,000-4,000 mg/day) taken for at least one year significantly improved heart function, particularly the left ventricular ejection fraction and peak oxygen consumption.
However, lower doses and shorter durations were not effective, and we found no major differences in safety measures like dropout rates or overall mortality between those taking omega-3 and those who were not.
Our findings revealed that high doses (2,000-4,000 mg/day) taken for at least one year significantly improved heart function, particularly the left ventricular ejection fraction and peak oxygen consumption.
However, lower doses and shorter durations were not effective, and we found no major differences in safety measures like dropout rates or overall mortality between those taking omega-3 and those who were not.
References
- Liepinsh E, Gukalova B, Krims-Davis K, Kuka J, Leduskrasta A, et al. EPA and DHA acylcarnitines are less cardiotoxic than are saturated and monounsaturated long-chain acylcarnitines. Biofactors. 2025;51:e70014. 10.1002/biof.70014
- Medoro A, Graziano F, Cardinale G, Voccola S, Zotti T, et al. The influence of FADS1 and ELOVL2 genetic polymorphisms on polyunsaturated fatty acid composition in response to fish oil supplementation. Lipids Health Dis. 2025;24:102. 10.1186/s12944-025-02513-w
- Horii K, Ono K, Sumi T, Higashihara M, Zaima N, et al. Eicosapentaenoic acid prevents atrial electrocardiographic impairments and atrial fibrillation in high fat diet mice. J Physiol Sci. 2025;75:100014. 10.1016/j.jphyss.2025.100014
- Dawczynski C, Drobner T, Weidauer T, Schlattmann P, Kiehntopf M, et al. Reduction of cardiovascular risk factors by the diet - Evaluation of the MoKaRi concept by a parallel-designed randomized study. Lipids Health Dis. 2025;24:88. 10.1186/s12944-025-02500-1
- Aggarwal R, Bhatt DL, Steg PG, Miller M, Brinton EA, et al. Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. J Am Heart Assoc. 2025;14:e038656. 10.1161/JAHA.124.038656
- Mao Q, Tian X, Wang X, Xu H, Zhang Y, et al. Global burden of cardiovascular diseases attributable to diet low in seafood omega-3 fatty acids from 1990~2021 and forecasting the future trends: A population-based study. PLoS One. 2025;20:e0316767. 10.1371/journal.pone.0316767
- Tseng PT, Zeng BY, Hsu CW, Liang CS, Stubbs B, et al. The Optimal Dosage and Duration of ω-3 PUFA Supplementation in Heart Failure Management: Evidence from a Network Meta-Analysis. Adv Nutr. 2025;16:100366. 10.1016/j.advnut.2025.100366
- Hemmati R, Bahrami Zanjanbar D, Shishesaz MI, Soleimani A, Yari T. The impact of Omega-3 supplementation on arrhythmia reduction in acute coronary syndrome patients: a randomized clinical trial. J Complement Integr Med. 2025;22:173. 10.1515/jcim-2024-0427
- Wang Y, Wu G, Wang Y, Rehman A, Yu L, et al. Recent developments, challenges, and prospects of dietary omega-3 PUFA-fortified foods: Focusing on their effects on cardiovascular diseases. Food Chem. 2025;470:142498. 10.1016/j.foodchem.2024.142498
- Dong S, Wang Y, Bian J, Chen H, Dong J, et al. The effect of omega-3 Polyunsaturated Fatty Acid (PUFA) prescription preparations on the prevention of clinical cardiovascular disease: a meta-analysis of RCTs. Nutr J. 2024;23:157. 10.1186/s12937-024-01051-y
- Jawad MA, O'Keefe JH, Tintle N, O'Keefe EL, Franco WG, et al. Association of Plasma Omega-3 Levels With Incident Heart Failure and Related Mortalities. Mayo Clin Proc. 2024;99:1895. 10.1016/j.mayocp.2024.08.007
- Brosolo G, Da Porto A, Marcante S, Capilupi F, Bertin N, et al. The role for ω-3 polyunsaturated and short chain fatty acids in hypertension: An updated view on the interaction with gut microbiota. Eur J Pharmacol. 2024;985:177107. 10.1016/j.ejphar.2024.177107
- Lee YQ, Tan KH, Chong MF. Biomarkers of PUFA and cardiovascular risk factors and events in healthy Asian populations: a systematic review. Br J Nutr. 2024;132:1474. 10.1017/S0007114524002708
- Li J, Nan W, Huang X, Meng H, Wang S, et al. Eicosapentaenoic acid induces macrophage Mox polarization to prevent diabetic cardiomyopathy. EMBO Rep. 2024;25:5507. 10.1038/s44319-024-00271-x
- Li ZH, Song WQ, Qiu CS, Li HM, Tang XL, et al. Fish oil supplementation, genetic susceptibility and risk of new-onset hypertension. Prev Med. 2024;189:108152. 10.1016/j.ypmed.2024.108152
- Hamaya R, Cook NR, Sesso HD, Buring JE, Manson JE. A Bayesian Analysis of the VITAL Trial: Effects of Omega-3 Fatty Acid Supplementation on Cardiovascular Events. Am J Clin Nutr. 2025. 10.1016/j.ajcnut.2025.02.028
- Liboriussen C, Nygaard L, Jensen JD, Schmidt EB, Glerup RI, et al. Low Plasma Marine N-3 Polyunsaturated Fatty Acids are Associated with Increased Risk of Cardiovascular Events in Patients Treated with Maintenance Hemodialysis. J Ren Nutr. 2025. 10.1053/j.jrn.2025.02.001
- Yunoki K, Matsumi H, Miyoshi T, Kubo M, Hata Y, et al. Clinical Significance of Serum Omega-3 Fatty Acids on Endothelial Function in Patients with Coronary Artery Disease Under Statin Therapy. J Cardiovasc Dev Dis. 2025;12. 10.3390/jcdd12020060
- Patil T, Gregory M, Savona N, Jarmukli N, Leonard CE. Evaluating the Real-World Safety of Icosapent Ethyl Versus Omega-3 Polyunsaturated Fatty Acid in Nationwide US Veterans Cohort: Examining Atrial Fibrillation and Bleeding Endpoints. Clin Drug Investig. 2025;45:69. 10.1007/s40261-024-01417-4
- Kim JY, Kong SYJ, Jung E, Cho YS. Omega-3 Fatty Acids as Potential Predictors of Sudden Cardiac Death and Cardiovascular Mortality: A Systematic Review and Meta-Analysis. J Clin Med. 2024;14. 10.3390/jcm14010026
- Lamon-Fava S. Associations between omega-3 fatty acid-derived lipid mediators and markers of inflammation in older subjects with low-grade chronic inflammation. Prostaglandins Other Lipid Mediat. 2025;176:106948. 10.1016/j.prostaglandins.2025.106948
- Fukuda T, Nakajima T, Hasegawa T, Amano H, Arikawa T, et al. Relationship Between Serum ω-3 Polyunsaturated Fatty Acid Concentration and Fatty Acid Fraction of Epicardial Adipose Tissue in Patients With Cardiovascular Disease. Cureus. 2024;16:e73417. 10.7759/cureus.73417
- O'Keefe EL, O'Keefe JH, Abuissa H, Metzinger M, Murray E, et al. Omega-3 and Risk of atrial fibrillation: Vagally-mediated double-edged sword. Prog Cardiovasc Dis. 2024. 10.1016/j.pcad.2024.11.003
- Choi JH, Park SE, Kim S. Antarctic Krill Oil Supplementation Attenuates Hypercholesterolemia, Fatty Liver, and Oxidative Stress in Diet-Induced Obese Mice. Nutrients. 2024;16. 10.3390/nu16213614
- So J, Yao JH, Magadmi R, Matthan NR, Lamon-Fava S. Sex differences in lipid mediators derived from omega-3 fatty acids in older individuals with low-grade chronic inflammation. Prostaglandins Leukot Essent Fatty Acids. 2024;203:102655. 10.1016/j.plefa.2024.102655
- Choi GY, Calder PC. The differential effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors: an updated systematic review of randomized controlled trials. Front Nutr. 2024;11:1423228. 10.3389/fnut.2024.1423228
- Follonier C, Rabassa G, Branca M, Carballo D, Koskinas K, et al. Eligibility for marine omega-3 fatty acid supplementation after acute coronary syndromes. Atheroscler Plus. 2024;58:1. 10.1016/j.athplu.2024.09.002
- Koutsaliaris IK, Pantazi D, Tsouka AN, Argyropoulou O, Tellis CC, et al. Differential Effect of Omega-3 Fatty Acids on Platelet Inhibition by Antiplatelet Drugs In Vitro. Int J Mol Sci. 2024;25. 10.3390/ijms251810136
- Ren Y, Chen B, Zhang H, Xu S. A cohort study reveals shared and distinct serum metabolic biomarkers for major adverse cardiovascular events in middle-aged and older adults. Geroscience. 2025. 10.1007/s11357-025-01544-6
- Arghavani H, Bilodeau JF, Rudkowska I. Association Between Circulating Fatty Acids and Blood Pressure: A Review. Curr Nutr Rep. 2025;14:15. 10.1007/s13668-024-00602-3
- Li J, Guo J, Yuen M, Yuen H, Peng Q. The comparative effects of ω-7 fatty acid-rich sea buckthorn oil and ω-3 fatty acid-rich DHA algal oil on improving high-fat diet-induced hyperlipidemia. Food Funct. 2025;16:1241. 10.1039/d4fo04961f
- Berkowitz L, Echeverría G, Salazar C, Faúndez C, Coe CL, et al. Lipidomic Signature of Healthy Diet Adherence and Its Association with Cardiometabolic Risk in American Adults. Nutrients. 2024;16. 10.3390/nu16233995
- Shi F, Chowdhury R, Sofianopoulou E, Koulman A, Sun L, et al. Association of circulating fatty acids with cardiovascular disease risk: analysis of individual-level data in three large prospective cohorts and updated meta-analysis. Eur J Prev Cardiol. 2025;32:233. 10.1093/eurjpc/zwae315
